New oral anticoagulants (NOACs) are emerging alternatives for prophylaxis and treatment of atrial fibrillation (AF) and venous thromboembolism (VTE). This review evaluated the comparative effectiveness of NOACs and warfarin for AF and VTE. It found that NOACs were superior to warfarin for some clinical outcomes, including mortality, in AF and were similar to warfarin for primary outcomes in VTE. Adverse effects of NOACs versus warfarin were generally consistent across treatment indications, but some varied by class.
Topics:
atrial fibrillation, anticoagulants, oral, warfarin, hemorrhage, direct thrombin inhibitor, dabigatran etexilate, venous ...
Ann Intern Med. 2012;157(11):796-807. doi:10.7326/0003-4819-157-10-201211200-00532